Table 2

Covariate balance between medication categories before and after inverse probability of treatment-weighted standardization

CovariateMaximum between-group standardized differencebefore weighting (%)Maximum between-group standardized differenceafter weighting (%)
Age40.65.4
Male10.67.4
Race
 White13.85.2
 Black15.65.7
 Asian8.18.1
 Pacific Islander4.12.4
 Native American8.44.5
Family history of CAD11.12.5
Tobacco8.07.0
Hypertension11.63.4
Hyperlipidemia9.05.0
BMI13.22.2
Framingham risk score19.85.8
PAD15.75.9
CHF30.86.1
COPD6.22.5
CKD75.714.7
Dialysis26.114.0
Depression13.12.5
PTSD14.14.3
Presentation
 Stable angina6.97.5
 Positive functional study15.74.2
 Ischemic heart disease5.91.7
 Chest pain13.82.0
Postangiography revascularization
 None10.74.6
 PCI6.23.5
 CABG8.04.2
Baseline HbA1c32.44.8
Diabetes duration16.65.3
  • BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; PTSD, post-traumatic stress disorder.